<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04936932</url>
  </required_header>
  <id_info>
    <org_study_id>BCCCIP001</org_study_id>
    <nct_id>NCT04936932</nct_id>
  </id_info>
  <brief_title>Laser Treatment of Basal Cell Carcinoma</brief_title>
  <official_title>Laser Treatment of Basal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sciton</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sciton</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Laser treatment of Basal cell carcinoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this pilot study is to examine the treatment of superficial basal cell&#xD;
      carcinoma (BCC) with laser technology. The laser modality that we plan to use is the&#xD;
      long-pulse Nd:YAG 1064nm laser, which is a non-ablative laser already shown to effectively&#xD;
      treat BCC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">January 29, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete clearance of BCC</measure>
    <time_frame>1 year</time_frame>
    <description>Histological confirmation of BCC clearance. Biopsy will be taken from the treatment site to confirm complete BCC clearance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cosmetic outcome</measure>
    <time_frame>1 year</time_frame>
    <description>Cosmetic outcome and any adverse effects of the laser treatment will be assessed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Basal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1064 Long-pulse Nd:YAG laser Fluence: 120 J/cm2 Number of passes: Single Spot size: 2 cm Pulse width: 8-10 msec</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Slow</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1064 Long-pulse Nd:YAG laser Fluence: 20-30 J/cm2 Number of passes: Multiple Spot size: 2 cm Pulse width: 8-10 msec</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>1064 nm long-pulse Nd:YAG laser</intervention_name>
    <description>BCC lesion will be treated with long-pulse 1064 laser</description>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>1064 nm long-pulse Nd:YAG laser</intervention_name>
    <description>BCC lesion will be treated with long-pulse 1064 laser</description>
    <arm_group_label>Slow</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy subjects 18 years of age or older&#xD;
&#xD;
          2. Lesion is biopsy-proven superficial BCC &lt;= 2.0 cm in largest diameter&#xD;
&#xD;
          3. BCC is on trunk or extremities&#xD;
&#xD;
          4. Seeks and is scheduled for treatment of BCC&#xD;
&#xD;
          5. Willing to have photographs taken of the treatment area&#xD;
&#xD;
          6. Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
          7. Agrees to adhere to the treatment and follow-up schedule and post treatment care&#xD;
             instructions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with a BCC lesion that requires excision. This would include relatively&#xD;
             larger lesions (&gt;2.0 cm in diameter), high risk lesions as defined by American Academy&#xD;
             of Dermatology as recurrent and sclerosing subtype BCC, or metastases.&#xD;
&#xD;
          2. Pregnancy&#xD;
&#xD;
          3. Subjects unable to follow-up for the full 12-months&#xD;
&#xD;
          4. Subjects not willing to have biopsy taken from the treatment area&#xD;
&#xD;
          5. Subjects with herpes simplex virus infection, impetigo or other disqualifying&#xD;
             condition as determined by a dermatologist on the treatment area or effecting healing&#xD;
             or outcome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris Robb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skin &amp; Allergy Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sciton</last_name>
    <phone>6504939155</phone>
    <email>clinicaltrials@sciton.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Skin &amp; Allergy Center</name>
      <address>
        <city>Spring Hill</city>
        <state>Tennessee</state>
        <zip>37174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>June 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Superficial Basal Cell Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

